These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39023617)

  • 1. Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated.
    Atalay F; Yeşilaltay A
    J Cancer Res Ther; 2024 Apr; 20(3):1049-1052. PubMed ID: 39023617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belinostat: first global approval.
    Poole RM
    Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
    Reimer P; Chawla S
    J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belinostat for the treatment of peripheral T-cell lymphomas.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
    Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia.
    Poh C; Arora M; Ghuman S; Tuscano J
    Acta Haematol; 2021; 144(1):95-99. PubMed ID: 32348994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
    Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
    J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
    Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.